Hydrochloric Acid

Hydrochloric Acid

SCHEMBL7784412

Cl.Nc1cccc(N)c1N

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA known ✓ P42336 1/20 0.50
GAA known ✓ P10253 1/20 0.38
CD44 P16070 1/20 0.58
CYP3A4 P08684 6/20 0.53
ALOX15 P16050 2/20 0.53
CASP1 P29466 2/20 0.53
CASP7 P55210 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
TSHR P16473 5/20 0.53
ALDH1A1 P00352 5/20 0.53
HSD17B10 Q99714 3/20 0.53
TDP1 Q9NUW8 2/20 0.53
HPGD P15428 2/20 0.53
L3MBTL1 Q9Y468 2/20 0.44
KEAP1 Q14145 1/20 0.43
NR4A2 P43354 1/20 0.39
RECQL P46063 1/20 0.39
PTPN5 P54829 1/20 0.39
MEN1 O00255 1/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL17110965 1.00 CD44 (0.58) CD44CYP3A4ALOX15CASP1CASP7
Hydrochloric Acid SCHEMBL9700979 1.00 CD44 (0.58) CD44CYP3A4ALOX15CASP1CASP7
SCHEMBL94635 0.96
Ammonia Solution, Strong SCHEMBL28226111 0.92 CD44 (0.58) CD44CYP3A4ALOX15CASP1CASP7
SCHEMBL28448539 0.92 CD44 (0.58) CD44CYP3A4ALOX15CASP1CASP7
Methane SCHEMBL28191162 0.92 CD44 (0.58) CD44CYP3A4ALOX15CASP1CASP7
SCHEMBL30335755 0.92 CD44 (0.58) CD44CYP3A4ALOX15CASP1CASP7
SCHEMBL28450972 0.92 CD44 (0.58) CD44CYP3A4ALOX15CASP1CASP7
Charcoal, Activated SCHEMBL29548810 0.92 CD44 (0.58) CD44CYP3A4ALOX15CASP1CASP7
SCHEMBL28288730 0.92 CD44 (0.58) CD44CYP3A4ALOX15CASP1CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114045170-B Method for preparing multicolor fluorescent carbon dots, fluorescent carbon dots prepared by method and application 嘉兴学院 2023-06-06 CN claimed
CN-115245759-A Self-supporting covalent organic framework film and preparation method thereof 中国科学技术大学 2022-10-28 CN claimed
CN-114045170-A Method for preparing multicolor fluorescent carbon dots, fluorescent carbon dots prepared by method and application of fluorescent carbon dots 嘉兴学院 2022-02-15 CN claimed
CN-114045170-B Method for preparing multicolor fluorescent carbon dots, fluorescent carbon dots prepared by method and application 嘉兴学院 2023-06-06 CN disclosed
CN-115245759-A Self-supporting covalent organic framework film and preparation method thereof 中国科学技术大学 2022-10-28 CN disclosed
CN-114045170-A Method for preparing multicolor fluorescent carbon dots, fluorescent carbon dots prepared by method and application of fluorescent carbon dots 嘉兴学院 2022-02-15 CN disclosed
CN-105348201-B A kind of hydroxyl benzimidazole diamine and preparation method thereof 中国科学院长春应用化学研究所 2018-07-03 CN disclosed
CN-105348201-A Hydroxyl-containing benzimidazole diamines and preparation method thereof CHANGCHUN APPLIED CHEMISTRY 2016-02-24 CN disclosed
EP-1140095-A1 (2-IMIDAZOLINE-2-YLAMINO) QUINOXALINE DERIVATIVES FOR THE TREATMENT OF PAIN Allergan Sales, Inc. (US) 2001-10-10 EP disclosed
WO-2000038684-A1 (2-IMIDAZOLIN-2-YLAMINO) QUINOXALINE DERIVATIVES FOR THE TREATMENT OF PAIN ALLERGAN SALES, INC. (US) 2000-07-06 WO disclosed
EP-0723447-A1 METHODS FOR USING (2-IMIDAZOLIN-2-YLAMINO) QUINOXALINE DERIVATIVES Allergan (US) 1996-07-31 EP disclosed
EP-0426390-B1 Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure ALLERGAN INC (US) 1995-05-10 EP disclosed
WO-1995010280-A1 METHODS FOR USING (2-IMIDAZOLIN-2-YLAMINO) QUINOXALINE DERIVATIVES ALLERGAN (US) 1995-04-20 WO disclosed
EP-0422878-B1 (2-Imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same ALLERGAN INC (US) 1994-04-27 EP disclosed
WO-1992013855-A1 (2-IMIDAZOLIN-2-YLAMINO) TETRAHYDROQUINOLAXINES AND METHODS FOR USING SAME ALLERGAN, INC. (US) 1992-08-20 WO disclosed